Stockreport

Ocugen (OCGN) Valuation Check After Encouraging Phase 2 ArMaDa Results For OCU410 [Yahoo! Finance]

Ocugen, Inc.  (OCGN) 
PDF Ocugen (OCGN) has drawn fresh investor attention after releasing full Phase 2 ArMaDa data for OCU410, showing a 46% reduction in macular lesion growth at 12 months and [Read more]